Tools
Stock profile

BIO-RAD LABORATORIES, INC. (BIO)

BIO · Latest close $370.17 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$370.17
As of Nov 18, 2026
Tracked funds holding
4 of 149
2026 Q2 13F filings
Opened / added
0 / 2
vs previous quarter
Trimmed / exited
2
vs previous quarter

BIO-RAD LABORATORIES, INC. (BIO) is held by 4 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds adding and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $1.2M sold). Latest close $370.17 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-1.2M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Ariel Investments · First Pacific Advisors · First Eagle Investment Management — 4 tracked funds hold BIO. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 3 sales ($1.2M). Insider trading

Often held alongside

VAIL RESORTS INC (MTN) · Envista Holdings Corp (NVST) · WATERS CORP /DE/ (WAT) · Avantor, Inc. (AVTR) · AGILENT TECHNOLOGIES, INC. (A) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Ariel Investments2.39%816,751ADDED (+3.9%) Q3 filed Nov 13
First Pacific Advisors1.46%401,861TRIMMED (-1.3%) Q3 filed Nov 12
First Eagle Investment Management1.26%2,606,219ADDED (+0.1%) Q3 filed Nov 10
Deerfield Management0.69%226,070HELD Q3 filed Nov 16
Southeastern Asset Management——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +20.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

390.34209.612024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding397 of 8,857 filers
Long-only filers among them396
Change vs 2026 Q1+13 net · 380 entered · 367 exited
Shares reported, all filers19,389,569
Reported value, all filers$5.5B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryLaboratory Analytical Instruments (SIC 3826)
Revenue · FY2025$2.6B
Net income · FY2025$759.9M
Total assets · FY2025$10.6B
Shares outstanding27,263,000
Market cap (at latest close)$10.1B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.

Short interest

Shares short · Oct 15, 20261,097,562
Share of shares outstanding4.03%
Days to cover4.84

Shares short at recent settlements — Jul 31, 2026: 1.4M · Aug 14, 2026: 1.3M · Aug 31, 2026: 1.1M · Sep 15, 2026: 999K · Sep 30, 2026: 1.2M · Oct 15, 2026: 1.1M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.

Fails to deliver

Shares failed to deliver · Oct 14, 2026336
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 2026<0.1%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 336.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Dec 31, 2025.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 3 sales by 3 insiders ($1.2M).

Source: SEC Form 4 filings. Open-market transactions only.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
May 28, 2026Alles Institute for Medical Research CorpDirector, 10% Stockholder700$219.3KMay 28, 2026SEC filing
May 11, 2026EVA ENGELHARDTOfficer550$135.6KMay 11, 2026SEC filing
Dec 2, 2025MICHAEL W CROWLEYOfficer776$248.0KDec 2, 2025SEC filing
Nov 18, 2025Alles Institute for Medical Research CorpDirector, 10% Stockholder760$228.8KNov 18, 2025SEC filing
Nov 6, 2025JAMES BARRYOfficer701$214.6KNov 6, 2025SEC filing
Aug 5, 2025MICHAEL W CROWLEYOfficer1,488$410.6KAug 5, 2025SEC filing
Mar 13, 2025Crowley MichaelOfficer3,000$780.0KMar 13, 2025SEC filing
Mar 11, 2025Alles Institute for Medical Research CorpDirector, 10% Stockholder410$101.5KMar 11, 2025SEC filing
Nov 6, 2024Last Andrew J.Officer3,000$1.1MNov 6, 2024SEC filing
Sep 12, 2024Last Andrew J.Officer1,600$514.5KSep 12, 2024SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Oct 30, 2025SCHEDULE 13D/A+12.1% (close Oct 31, 2025 → Nov 17, 2026)

Reference close is the first trading day after the filing (Oct 31, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Oct 30, 2025Norman D. SchwartzSC 13D/A4,929,03697.2%Sep 25, 2025SEC filing
Oct 30, 2025Norman D. SchwartzSC 13D/A3,228,92214.6%Sep 25, 2025SEC filing
Oct 28, 2025Norman D. SchwartzSC 13D/A4,929,03697.2%Sep 25, 2025SEC filing
Oct 28, 2025Norman D. SchwartzSC 13D/A3,228,92214.6%Sep 25, 2025SEC filing
Oct 17, 2025BlackRock, Inc.SC 13G/A1,618,1237.4%Sep 30, 2025SEC filing
Aug 6, 2025First Eagle Investment Management, LLCSC 13G/A2,528,321.4311.4%Jun 30, 2025SEC filing
Jul 18, 2025Alice N. SchwartzSC 13D/A2,732,07312.3%May 1, 2025SEC filing
May 5, 2025First Eagle Investment Management, LLCSC 13G/A2,294,260.9610.0%Apr 30, 2025SEC filing
May 5, 2025First Eagle Investment Management, LLCSC 13G1,569,782.36.8%Mar 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Laboratory Analytical Instruments (SIC 3826). No standing committee maps to this industry under the site’s jurisdiction rule — see Methodology.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 27 Lobbying Disclosure Act filings named this company as client, 2020–2026; most common issues: Health Issues (27), Defense (13), Medicare/Medicaid (5).

Federal contracts: $33.9M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$6.2M
FY2022$6.6M
FY2023$6.5M
FY2024$5.8M
FY2025$4.0M
FY2026$4.8M

Largest awards collected

Award IDAgencyAmountStart
36C26225P0701Department of Veterans Affairs$397.0KFeb 14, 2025
VA26016P3005Department of Veterans Affairs$391.7KSep 27, 2016
36C25723P0713Department of Veterans Affairs$309.6KAug 31, 2023
75N96022P00312Department of Health and Human Services$282.5KSep 22, 2022
75N91021P00302Department of Health and Human Services$234.5KAug 1, 2021

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Deep Value (Templeton) — Stocks that are cheap against both earnings and assets

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Deep Value (Templeton) — P/E: 13.80 · P/B: 1.41 · Latest EPS: 27.85 · Dividend yield: 0.0%

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2023 Q2, ranked #39 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together757.1%+1.8%+6.9%-5.1%
Share count tripled (3x)333.3%-1.0%+5.3%-6.3%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold BIO — ranked by lift, the co-holding pattern described in Methodology: VAIL RESORTS INC (MTN) · Envista Holdings Corp (NVST) · WATERS CORP /DE/ (WAT) · Avantor, Inc. (AVTR) · AGILENT TECHNOLOGIES, INC. (A) · ILLUMINA, INC. (ILMN) · METTLER TOLEDO INTERNATIONAL INC/ (MTD) · BRUKER CORP (BRKR).

6 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 4, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Aug 4, 20262.02 Results of Operations and Financial Condition · 2.05 Costs Associated with Exit or Disposal Activities · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Apr 30, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

VAIL RESORTS INC (MTN) · Track Record: how the signals scored · Practice timing on BIO

One email a week: the week’s new filings and research. Subscribe free

← BIL  ·  BIOA →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.